{
    "nct_id": "NCT05642455",
    "official_title": "A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors",
    "inclusion_criteria": "* Age 2-21 years\n* Body weight ≥ 10 kg\n* Subject has histologically confirmed diagnosis of any one of the following cancers: (A) Synovial Sarcoma, (B) MPNST, (C) Neuroblastoma, or (D) Osteosarcoma\n* Must have previously received a systemic chemotherapy\n* Measurable disease according to RECIST v1.1 (or INCR, 2017 Neuroblastoma only).\n* HLA-A*02 positive\n* Tumor shows MAGE-A4 expression confirmed by central laboratory.\n* Performance Status: ECOG 0-1 or Lansky Score ≥ 80\nHealthy volunteers allowed\nMust have minimum age of 2 Years\nMust have maximum age of 21 Years",
    "exclusion_criteria": "* HLA-A*02:05 in either allele; or any A*02 having same protein sequence as HLA-A*02:05\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide.\n* History of autoimmune or immune mediated disease\n* Known central nervous system (CNS) metastases.\n* Other prior malignancy that is not considered by the Investigator to be in complete remission\n* Clinically significant cardiovascular disease\n* Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or human T cell leukemia virus\n* Pregnant or breastfeeding",
    "miscellaneous_criteria": ""
}